liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors
Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
2017 (English)In: British Journal of Pharmacology, ISSN 0007-1188, E-ISSN 1476-5381, Vol. 174, no 24, p. 4600-4610Article in journal (Refereed) Published
Abstract [en]

Mutations in components of the Wnt pathways are a frequent cause of many human diseases, particularly cancer. Despite the fact that a causative link between aberrant Wnt signalling and many types of human cancers was established more than a decade ago, no Wnt signalling inhibitors have made it into the clinic so far. One reason for this is that no pathway-specific kinase is known. Additionally, targeting the protein-protein interactions needed to transduce the signal has not met with success so far. Complicating the search for and use of inhibitors is the complexity of the cascades triggered by the Wnts and their paramount biological importance. Wnt/β-catenin signalling is involved in virtually all aspects of embryonic development and in the control of the homeostasis of adult tissues. Encouragingly, however, in recent years, first successes with Wnt-pathway inhibitors have been reported in mouse models of disease. In this review, we summarize possible roads to follow during the quest to pharmacologically modulate the Wnt signalling pathway in cancer.

Place, publisher, year, edition, pages
John Wiley & Sons, 2017. Vol. 174, no 24, p. 4600-4610
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:liu:diva-150048DOI: 10.1111/bph.13864ISI: 000427839000006PubMedID: 28521071Scopus ID: 2-s2.0-85020943692OAI: oai:DiVA.org:liu-150048DiVA, id: diva2:1237365
Available from: 2018-08-08 Created: 2018-08-08 Last updated: 2018-08-22Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Cantù, Claudio
In the same journal
British Journal of Pharmacology
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf